Crocin as a novel therapeutic agent against colitis

Area of Science:

• Pharmacology
• Gastroenterology
• Immunology

Background:

• Ulcerative colitis (UC) is a chronic inflammatory bowel disease with significant global health impact.
• Current treatments for UC have limitations, necessitating the exploration of novel therapeutic agents.
• Crocin, a key pharmacologically active component of saffron, possesses known anti-inflammatory properties.

Purpose of the Study:

• To evaluate the therapeutic efficacy of crocin in a dextran sodium sulfate (DSS)-induced mouse model of colitis.
• To assess crocin's impact on disease activity and colonic histopathology.

Main Methods:

• Experimental colitis was induced in mice using 1.5% DSS in drinking water for one week.
• Animals were pre-treated with either 50-ppm or 200-ppm crocin for three weeks prior to DSS administration.
• Disease activity was assessed by monitoring body weight, diarrhea, rectal bleeding, and colon length; histological analysis of colon tissues was performed.

Main Results:

• Crocin pre-treatment significantly attenuated DSS-induced colitis, reducing disease activity index, including body weight loss, diarrhea, rectal bleeding, and colon shortening.
• Histopathological examination revealed that crocin significantly decreased colon tissue damage and inflammation.
• These anti-inflammatory effects were observed in a dose-dependent manner.

Conclusions:

• Crocin demonstrates significant therapeutic potential in mitigating experimental colitis.
• Crocin acts, at least partially, by eliciting anti-inflammatory responses.
• Crocin is a promising novel therapeutic agent with low toxicity and potential clinical significance for treating colitis.